A
Dietary SupplementAlcohol consumption (32 g/day) for 4 weeks
NCT Number: NCT00364767
Moderate alcohol consumption is associated with a decreased risk of diabetes type 2. This association could be mediated by an improvement of insulin sensitivity with moderate alcohol consumption. Patients with diabetes type 2 or impaired glucose tolerance often may have decreased fat oxidative capacity or oxidative phosphorylation in tissue such as muscle. This could lead to accumulation triglyceride storage in muscle, which could interfere with insulin signaling. Whether such mechanism can also play a role with moderate alcohol consumption is unknown and will be investigated in this study.
In addition, moderate alcohol consumption with a meal can lead to delayed hypoglycemia in type 1 diabetes patients. How moderate alcohol consumption affects postprandial glycemic response in healthy subjects is unknown. This is a secondary objective of this trial.
Looking for future studies?
Notify Me18 year–40 year
Male
Interventional
Not applicable
To investigate the effect of moderate alcohol consumption on
Design : Open, randomized, partially diet-controlled, placebo controlled cross-over design
Participants
Study substances
Duration: 2 treatment periods of 4 weeks (28 days)
Test parameters:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Alcohol consumption (32 g/day) for 4 weeks
Water
Time frame: 4 weeks
Time frame: 4 weeks
Time frame: 4 weeks
TNO
Other
The Effect of Moderate Alcohol Consumption on Markers of Oxidative Phosphorylation and Lipid Oxidation and on Postprandial Glycemic Control in Healthy, Lean and Overweight, Young Men
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03267758
Cardiovascular Disease, Cardiovascular Diseases
Milwaukee, Wisconsin, United States
View Trial DetailsNCT01394952
Cardiovascular Disease, Cardiovascular Diseases
Mobile, Alabama, United States
View Trial DetailsNCT02518503
Cardiovascular Disease, Cardiovascular Diseases
View Trial DetailsNCT00185159
Cardiovascular Disease, Cardiovascular Diseases
Darmstadt, Germany
View Trial Details